For clinicians

Quick clinical context, intended use, and how patients can get started.

Clinical overview

ProstateGuard measures the Prostate Health Index (phi), an FDA-approved blood test analysis used as an aid in distinguishing prostate cancer from benign prostatic conditions in appropriate men (often age 50+ with PSA in a borderline range and non-suspicious DRE).

  • Supports shared decision-making around biopsy
  • Can help reduce unnecessary biopsies in appropriate patients
  • Report is designed for both clinician and patient readability

Workflow

  1. Patient orders ProstateGuard kit
  2. Upper-arm capillary sample is collected at home with Tasso®
  3. Sample shipped to CLIA-certified lab for analysis
  4. Patient receives report and is prompted to review next steps with their clinician
Prostate biopsy is required to confirm cancer. The test is intended as an aid—not a standalone diagnosis.

Suggested next-step pathways

Clinicians may consider repeat labs, MRI, or biopsy based on the total clinical picture (symptoms, PSA trend, family history, exam findings, and patient preference). Use your clinical judgment and local guidelines.